title: Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.
abstract: Prophylaxis with regular infusions of factor VIII (FVIII)- or factor IX (FIX)- containing products is the mainstay of modern hemophilia care. However, this therapeutic regimen is inconvenient, requiring repeated intravenous injections from childhood. Approaches meant to prolong the half-life of FVIII and FIX in plasma have been developed in order to improve the feasibility and acceptability of replacement therapy, extending protection from bleeding, reducing infusion frequency and hence the need for venous access devices in young children. Several strategies have been implemented to enhance the pharmacokinetics of clotting factors, including conjugation with polyethylene glycol and the production by genetic engineering of fusion proteins containing the coagulation factors linked to a long-lived plasma protein such as albumin or the Fc fragment of immunoglobulin (Ig)G. The latter technology is one of the most promising, since the prolongation of FVIII and FIX half-life is obtained by exploiting the physiological binding of the Fc domain to the neonatal Fc receptor. Fc fusion monomers have been obtained with both recombinant FVIII (rFVIIIFc) and FIX (rFIXFc), and data from preclinical and clinical studies showed improved pharmacokinetics for both factors, which are produced in human embryonic kidney (HEK) 293 cells, thus ensuring full human post-translational modifications. In Phase I/IIa studies, rFVIIIFc and rFIXFc showed 1.5-1.7 fold and 3.0-4.0 fold longer elimination half-life, respectively. Similar data have been obtained in the Phase III clinical studies with rFVIIIFc and rFIX-Fc published recently. Both drugs were satisfactorily safe, particularly with respect to immunogenicity, and no serious adverse event was observed.
authors.affiliation: Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
authors.forename: Maria Elisa
authors.initials: ME
authors.lastname: Mancuso
authors.affiliation: Scientific Direction, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
authors.forename: Pier Mannuccio
authors.initials: PM
authors.lastname: Mannucci
mesh_terms: D005164:Factor IX / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005169:Factor VIII / Q000493:pharmacokinetics / Q000627:therapeutic use*; D057809:HEK293 Cells; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
chemical_list: D011993:Recombinant Fusion Proteins; D005169:Factor VIII; D005164:Factor IX
keywords: factor IX; factor VIII; long-acting molecules
references.citation: N Engl J Med. 1996 Jun 27;334(26):1697-702
references.pmid: 8637514
references.citation: N Engl J Med. 2001 Jun 7;344(23):1773-9
references.pmid: 11396445
references.citation: Blood. 2012 Sep 20;120(12):2405-11
references.pmid: 22859609
references.citation: J Thromb Haemost. 2009 Mar;7(3):413-20
references.pmid: 19143924
references.citation: Protein Expr Purif. 2012 Jul;84(1):147-53
references.pmid: 22580292
references.citation: Biotechnol Genet Eng Rev. 2012;28:147-75
references.pmid: 22616486
references.citation: Int Immunol. 2003 Feb;15(2):187-95
references.pmid: 12578848
references.citation: J Thromb Haemost. 2010 Feb;8(2):269-75
references.pmid: 19943875
references.citation: J Cell Biol. 1983 Feb;96(2):338-46
references.pmid: 6403551
references.citation: N Engl J Med. 2005 Sep 15;353(11):1114-23
references.pmid: 16162882
references.citation: Clin Ther. 1999 Jan;21(1):75-87; discussion 1-2
references.pmid: 10090426
references.citation: J Exp Med. 2002 Aug 5;196(3):303-10
references.pmid: 12163559
references.citation: Experientia. 1992 Jan 15;48(1):22-6
references.pmid: 1737572
references.citation: Hum Immunol. 2001 Feb;62(2):93-105
references.pmid: 11182218
references.citation: Blood. 2001 Dec 15;98(13):3600-6
references.pmid: 11739163
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9763-8
references.pmid: 15210944
references.citation: Blood. 2012 Jan 19;119(3):666-72
references.pmid: 22110246
references.citation: N Engl J Med. 2007 Aug 9;357(6):535-44
references.pmid: 17687129
references.citation: Thromb Haemost. 1997 Jul;78(1):261-5
references.pmid: 9198163
references.citation: N Engl J Med. 2013 Dec 12;369(24):2313-23
references.pmid: 24304002
references.citation: J Immunol. 2004 Feb 15;172(4):2021-9
references.pmid: 14764666
references.citation: Blood. 2012 Mar 29;119(13):3031-7
references.pmid: 22223821
references.citation: J Am Soc Nephrol. 2000 Apr;11(4):632-639
references.pmid: 10752522
references.citation: Blood. 2010 Mar 11;115(10):2057-64
references.pmid: 20056791
references.citation: Blood. 2012 Mar 29;119(13):3024-30
references.pmid: 22246033
references.citation: Blood Rev. 2011 Jan;25(1):11-5
references.pmid: 21030121
references.citation: J Thromb Haemost. 2013 Jan;11(1):132-41
references.pmid: 23205847
references.citation: J Thromb Haemost. 2011 Apr;9(4):700-10
references.pmid: 21255253
references.citation: Trends Cell Biol. 2005 Jan;15(1):5-9
references.pmid: 15653072
references.citation: Immunology. 1997 Sep;92(1):69-74
references.pmid: 9370926
references.citation: Blood. 2014 Jan 16;123(3):317-25
references.pmid: 24227821
references.citation: N Engl J Med. 2001 Jul 26;345(4):248-55
references.pmid: 11474662